PEPTIDOGLYCAN ANALYSIS OF VSE AND VRE

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 屎肠球菌是一种机会致病菌，引起相当大比例的肠球菌人类感染，特别是在医院。 由于肠球菌对许多种类的抗生素表现出内在的耐药性（例如，青霉素类），最成功的治疗是糖肽类。 糖肽通过扰乱细胞壁的完整性引起细菌细胞死亡。 最强大的糖肽，所谓的“最后的药物”，是万古霉素。 然而，自1988年以来，万古霉素耐药感染的发生率迅速增加。 解决肠球菌耐药问题需要了解细胞壁肽聚糖（万古霉素的潜在结合位点）的生物合成和组织。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Enterococcus faecium, an opportunistic pathogen, causes a substantial proportion of enterococcal human infections, particularly in hospitals. Due to the intrinsic resistance that enterococci demonstrate towards many categories of antibiotics (e.g., penicillins), the most successful treatment has been glycopeptides. Glycopeptides cause bacterial cell death by perturbing the integrity of the cell wall. The most powerful glycopeptide, the so-called "drug of last resort," is vancomycin. However, the incidence of infections resistant to vancomycin has increased rapidly since 1988. Solving the problem of enterococcal resistance requires an understanding of the biosynthesis and organization of the cell-wall peptidoglycan, a potential binding site of vancomycin.